Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Calliditas Therapeutics AB
Headquarters: Stockholm, Sweden
Website: N/A
Year Founded: 2004
Status: Acquired
BioCentury | Oct 22, 2024
Product Development
Otsuka to take advantage of newly charted accelerated pathway for IgA nephropathy
BioCentury’s Clinical Report analyzes a pair of GLP-1 agonist updates, plus data from Amylyx’s ALS therapy in a new indication, and more
BioCentury | Jul 31, 2024
Product Development
Clinical Report: BioNTech claims mRNA cancer vaccine success
Plus data from NewAmsterdam, Pfizer, Calliditas, Ventyx and Viking
BioCentury | Jun 4, 2024
Deals
Biotech M&A, Biosecure expands & ASCO update: a BioCentury podcast
An M&A quartet. House China committee’s new focus. Colorectal cancer immunotherapies.
BioCentury | May 30, 2024
Product Development
Renal therapies get disease-specific
Endpoint innovation and success stories are driving a surge in renal disease drug development
BioCentury | May 29, 2024
Deals
Deals Report: Three $1B+ takeouts highlight demand in immunology, renal
Plus: Takeda-Degron to develop molecular glue degraders; Lilly-Aktis collaborate on radiopharmaceuticals; and more
BioCentury | May 28, 2024
Deals
Asahi Kasei rides renal momentum with $1.1B Calliditas takeout
Deal gives Japanese pharma Tarpeyo, first drug approved to treat IgA nephropathy
BioCentury | May 7, 2024
Product Development
Clinical report: Calliditas data provide mixed support for anti-fibrotic cancer mechanism
Plus: J&J aiming to replace bladder cancer surgery with TAR-210, and updates from Merck, GlycoMimetics, EyePoint and more
BioCentury | Apr 12, 2024
Deals
In $4.9B Alpine deal, Vertex sees best-in-class therapy with room for label expansions
Buyer believes povetacicept can outshine others in BAFF/APRIL class, even if not first to market — and can become a pipeline-in-a-product
BioCentury | Jan 9, 2024
Management Tracks
Germano succeeds Starr as Sage chair
Plus: CEO changes at Xoma, Affimed, and updates from ArriVent, Calliditas, Prime, Caribou, Janux and Insitro
BioCentury | Dec 21, 2023
Finance
Dec. 20 Quick Takes: CNS and topical TYK2 inhibitor company Sudo raises $116M series B
Plus: Dynamk’s Kranjac launches new equity firm, PureTech reveals newcos and updates from bluebird, Calliditas and Merck
Items per page:
1 - 10 of 50